X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs GSK PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS GSK PHARMA NOVARTIS/
GSK PHARMA
 
P/E (TTM) x 432.4 50.1 862.5% View Chart
P/BV x 30.5 10.4 294.4% View Chart
Dividend Yield % 1.5 2.8 53.9%  

Financials

 NOVARTIS   GSK PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
GSK PHARMA
Mar-18
NOVARTIS/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs7582,760 27.5%   
Low Rs5792,040 28.4%   
Sales per share (Unadj.) Rs228.4339.0 67.4%  
Earnings per share (Unadj.) Rs31.741.4 76.6%  
Cash flow per share (Unadj.) Rs32.845.9 71.4%  
Dividends per share (Unadj.) Rs10.0035.00 28.6%  
Dividend yield (eoy) %1.51.5 102.6%  
Book value per share (Unadj.) Rs297.1242.9 122.3%  
Shares outstanding (eoy) m24.6984.70 29.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.97.1 41.3%   
Avg P/E ratio x21.157.9 36.3%  
P/CF ratio (eoy) x20.452.3 39.0%  
Price / Book Value ratio x2.29.9 22.8%  
Dividend payout %31.584.5 37.3%   
Avg Mkt Cap Rs m16,505203,280 8.1%   
No. of employees `0000.7NA-   
Total wages/salary Rs m1,4455,234 27.6%   
Avg. sales/employee Rs Th8,441.3NM-  
Avg. wages/employee Rs Th2,163.6NM-  
Avg. net profit/employee Rs Th1,173.1NM-  
INCOME DATA
Net Sales Rs m5,63928,715 19.6%  
Other income Rs m1,718545 315.0%   
Total revenues Rs m7,35729,260 25.1%   
Gross profit Rs m-635,059 -1.2%  
Depreciation Rs m25380 6.7%   
Interest Rs m552 2,765.0%   
Profit before tax Rs m1,5755,222 30.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m7921,892 41.8%   
Profit after tax Rs m7843,508 22.3%  
Gross profit margin %-1.117.6 -6.3%  
Effective tax rate %50.336.2 138.7%   
Net profit margin %13.912.2 113.7%  
BALANCE SHEET DATA
Current assets Rs m9,52221,815 43.6%   
Current liabilities Rs m3,29615,999 20.6%   
Net working cap to sales %110.420.3 545.1%  
Current ratio x2.91.4 211.9%  
Inventory Days Days3764 57.6%  
Debtors Days Days2819 152.1%  
Net fixed assets Rs m4612,475 0.4%   
Share capital Rs m123847 14.6%   
"Free" reserves Rs m7,21319,726 36.6%   
Net worth Rs m7,33620,573 35.7%   
Long term debt Rs m06 0.0%   
Total assets Rs m11,10539,475 28.1%  
Interest coverage x29.52,612.0 1.1%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.7 69.8%   
Return on assets %7.68.9 85.0%  
Return on equity %10.717.1 62.6%  
Return on capital %22.226.2 84.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m61564 10.7%   
Fx outflow Rs m3,6307,429 48.9%   
Net fx Rs m-3,570-6,865 52.0%   
CASH FLOW
From Operations Rs m1,6104,728 34.1%  
From Investments Rs m687-1,042 -65.9%  
From Financial Activity Rs m-2,677-3,066 87.3%  
Net Cashflow Rs m-380620 -61.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 50.7 147.9%  
Indian inst/Mut Fund % 2.0 10.2 19.6%  
FIIs % 1.6 23.8 6.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 15.4 139.6%  
Shareholders   41,647 102,036 40.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  PFIZER  DR. DATSONS LABS  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Jet Airways and Yes Bank - What's Next for these Beaten Down Stocks?(Podcast)

Jet Airways and Yes Bank, both once market darlings are now being shunned by market participants. The National Stock Exchange (NSE) exchange notified that the shares of the airline.

Related Views on News

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

The Best 4 Small-cap Stocks to Buy(The 5 Minute Wrapup)

Jun 3, 2019

In the sometimes good sometimes bad market of small caps, there are strong buying opportunities available today. But this great opportunity won't last forever.

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Top 7 Stocks to Profit from Modi's Repeat Performance(Profit Hunter)

Jun 3, 2019

The long-term India story looks promising with the Modi government back in power. Which stocks are likely to go up the most?

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jun 14, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS